

References Herbal Solutions for Anxiety Disorders in Children

Beesdo, K., Knappe, S., & Pine, D. S. (2009). Anxiety and Anxiety Disorders in Children and Adolescents: Developmental Issues and Implications for DSM-V. *The Psychiatric Clinics of North America*, 32(3), 483-524.

Rapee, R. M., Schniering, C. A., & Hudson, J. L. (2009). Anxiety Disorders During Childhood and Adolescence: Origins and Treatment. *Annual Review of Clinical Psychology*, 5, 311-341.

Freeman, J. B., & Garcia, A. M. (2008). *Family-Based Treatment for Young Children With OCD: Therapist Guide*. Oxford University Press.

Koet LB, de Schepper EI, Bohnen AM, Bindels PJ, Gerger H. Anxiety problems in children and adolescents: a population-based cohort study on incidence and management in Dutch primary care. *Br J Gen Pract*. 2022 May 26;72(719):e405-e412. doi: 10.3399/BJGP.2021.0557. Erratum in: *Br J Gen Pract*. 2024 Mar 27;74(741):155. doi: 10.3399/bjgp24X737037. PMID: 35440466; PMCID: PMC9037188.

Racine N, McArthur BA, Cooke JE, Eirich R, Zhu J, Madigan S. Global Prevalence of Depressive and Anxiety Symptoms in Children and Adolescents During COVID-19: A Meta-analysis. *JAMA Pediatr*. 2021 Nov 1;175(11):1142-1150. doi: 10.1001/jamapediatrics.2021.2482. PMID: 34369987; PMCID: PMC8353576.

March, J. S., & Mulle, K. (1998). *OCD in Children and Adolescents: A Cognitive-Behavioral Treatment Manual*. Guilford Press.

Birmaher, B., Khetarpal, S., Brent, D., Cully, M., Balach, L., Kaufman, J., & Neer, S. M. (1997). The Screen for Child Anxiety Related Emotional Disorders (SCARED): Scale construction and psychometric characteristics. *Journal of the American Academy of Child and Adolescent Psychiatry*, 36(4), 545-553.

Spence, S. H. (1998). A measure of anxiety symptoms among children. *Behaviour Research and Therapy*, 36(5), 545-566.

Harit MK, Mundhe N, Tamoli S Sr, Pawar V, Bhapkar V, Kolhe G, Mahadik S, Kulkarni A, Agarwal A. Randomized, Double-Blind, Placebo-Controlled, Clinical Study of *Passiflora incarnata* in Participants With Stress and Sleep Problems. *Cureus*. 2024 Mar 20;16(3):e56530. doi: 10.7759/cureus.56530. PMID: 38646244; PMCID: PMC11026993.

Janda K, Wojtkowska K, Jakubczyk K, Antoniewicz J, Skonieczna-Żydecka K. *Passiflora incarnata* in Neuropsychiatric Disorders-A Systematic Review. *Nutrients*. 2020 Dec 19;12(12):3894. doi: 10.3390/nu12123894. PMID: 33352740; PMCID: PMC7766837.

Dos Reis Izolan L, da Silva DM, Oliveira HBL, de Oliveira Salomon JL, Peruzzi CP, Garcia SC, Dallegrave E, Zanotto C, Elisabetsky E, Gonçalves CA, Arbo MD, Konrath EL, Leal MB. Sintocalmy, a *Passiflora incarnata* Based Herbal, Attenuates Morphine Withdrawal in Mice.

Neurochem Res. 2021 May;46(5):1092-1100. doi: 10.1007/s11064-021-03237-w. Epub 2021 Feb 5. PMID: 33544325.

Amini F, Amini-Khoei H, Haratizadeh S, Setayesh M, Basiri M, Raeiszadeh M, Nozari M. Hydroalcoholic extract of *Passiflora incarnata* improves the autistic-like behavior and neuronal damage in a valproic acid-induced rat model of autism. *J Tradit Complement Med*. 2023 Feb 23;13(4):315-324. doi: 10.1016/j.jtcme.2023.02.005. PMID: 37396155; PMCID: PMC10310915.

Zanardi R, Carminati M, Fazio V, Maccario M, Verri G, Colombo C. Add-On Treatment with *Passiflora incarnata* L., herba, during Benzodiazepine Tapering in Patients with Depression and Anxiety: A Real-World Study. *Pharmaceuticals (Basel)*. 2023 Mar 10;16(3):426. doi: 10.3390/ph16030426. PMID: 36986524; PMCID: PMC10056302.

Akhondzadeh S, Mohammadi M, Momeni F. (2005). *Passiflora incarnata* in the treatment of attention-deficit hyperactivity disorder in children and adolescents. *Clin Pract*, 2 (4):609–614.

Noorazar SG, Mirzaei M, Kalejahi P. Iranian Traditional Medicine for Treatment of Attention Deficit Disorder with Hyperactivity in Children: A Systematic Review of Randomized Controlled Trials. *Iran J Public Health*. 2024 Feb;53(2):280-292. doi: 10.18502/ijph.v53i2.14913. PMID: 38894827; PMCID: PMC11182478.

Miroddi M, Calapai G, Navarra M, Minciullo PL, Gangemi S. *Passiflora incarnata* L.: ethnopharmacology, clinical application, safety and evaluation of clinical trials. *J Ethnopharmacol*. 2013 Dec 12;150(3):791-804. doi: 10.1016/j.jep.2013.09.047. Epub 2013 Oct 17. PMID: 24140586.

Petrisor G, Motelica L, Craciun LN, Oprea OC, Ficai D, Ficai A. *Melissa officinalis*: Composition, Pharmacological Effects and Derived Release Systems-A Review. *Int J Mol Sci*. 2022 Mar 25;23(7):3591. doi: 10.3390/ijms23073591. PMID: 35408950; PMCID: PMC8998931.

Gromball J, Beschorner F, Wantzen C, Paulsen U, Burkart M. Hyperactivity, concentration difficulties and impulsiveness improve during seven weeks' treatment with valerian root and lemon balm extracts in primary school children. *Phytomedicine*. 2014 Jul-Aug;21(8-9):1098-103. doi: 10.1016/j.phymed.2014.04.004. Epub 2014 May 15. PMID: 24837472.

Kennedy DO, Little W, Scholey AB. Attenuation of laboratory-induced stress in humans after acute administration of *Melissa officinalis* (Lemon Balm). *Psychosom Med*. 2004 Jul-Aug;66(4):607-13. doi: 10.1097/01.psy.0000132877.72833.71. PMID: 15272110.

Müller SF, Klement S. A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. *Phytomedicine*. 2006 Jun;13(6):383-7. doi: 10.1016/j.phymed.2006.01.013. Epub 2006 Feb 17. PMID: 16487692.

Prasanth DSNBK, Murahari M, Chandramohan V, et al. In-silico strategies of some selected phytoconstituents from *Melissa officinalis* as SARS CoV-2 main protease and spike protein (COVID-19) inhibitors. *Mol Simul*. 2021;47(6):457-470. doi:10.1080/08927022.2021.1880576

Elekofehinti OO, Iwaloye O, Famusiwa CD, Akinseye O, Rocha JBT. Identification of Main Protease of Coronavirus SARS-CoV-2 (Mpro) Inhibitors from *Melissa officinalis*. *Curr Drug Discov Technol*. 2021;18(5):38-52. doi:10.2174/1570163817999200918103705

Pourghanbari G, Nili H, Moattari A, Mohammadi A, Iraj A. Antiviral activity of the oseltamivir and *Melissa officinalis* L. essential oil against avian influenza A virus (H9N2). *VirusDisease*. 2016;27(2):170-178. doi:10.1007/s13337-016-0321-0

Jalali P, Moattari A, Mohammadi A, Ghazanfari N, Pourghanbari G. *Melissa officinalis* efficacy against human influenza virus (New H1N1) in comparison with oseltamivir. *Asian Pac J Trop Dis*. 2016;6(9):714-717. doi:10.1016/S2222-1808(16)61115-5

Allahverdiyev A, Duran N, Ozguven M, Koltas S. Antiviral activity of the volatile oils of *Melissa officinalis* L. against Herpes simplex virus type-2. *Phytomedicine*. 2004;11(7):657-661. doi:10.1016/j.phymed.2003.07.014

Melissa officinalis Extract Inhibits Attachment of Herpes Simplex Virus in vitro | Chemotherapy | Karger Publishers. Accessed November 3, 2023. <https://karger.com/che/article-abstract/58/1/70/67076/Melissa-officinalis-Extract-Inhibits-Attachment-of?redirectedFrom=fulltext>
Nolkemper S, Reichling J, Stintzing FC, Carle R, Schnitzler P. Antiviral Effect of Aqueous Extracts from Species of the Lamiaceae Family against Herpes simplex Virus Type 1 and Type 2 in vitro. *Planta Med*. 2006;72(15):1378-1382. doi:10.1055/s-2006-951719

Kim IS, Hwang CW, Yang WS, Kim CH. Multiple Antioxidative and Bioactive Molecules of Oats (*Avena sativa* L.) in Human Health. *Antioxidants (Basel)*. 2021 Sep 13;10(9):1454. doi: 10.3390/antiox10091454. PMID: 34573086; PMCID: PMC8471765.

Sayed AM, Morsy S, Tawfik GM, Naveed S, Minh-Duc NT, Hieu TH, Ali ZA, Shinkar A, Doheim MF, Hashan MR, Huy NT. The best route of administration of lavender for anxiety: a systematic review and network meta-analysis. *Gen Hosp Psychiatry*. 2020 May-Jun;64:33-40. doi: 10.1016/j.genhosppsych.2020.02.001. Epub 2020 Feb 13. PMID: 32088511.

Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Lavender. [Updated 2023 Sep 15]. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK501865/>

Cavanagh HM, Wilkinson JM. Biological activities of lavender essential oil. *Phytother Res*. 2002 Jun;16(4):301-8. doi: 10.1002/ptr.1103. PMID: 12112282.

Mijatovic S, Stankovic JA, Calovski IC, Dubljanin E, Pljevljakusic D, Bigovic D, Dzamic A. Antifungal Activity of *Lavandula angustifolia* Essential Oil against *Candida albicans*: Time-Kill Study on Pediatric Sputum Isolates. *Molecules*. 2022 Sep 24;27(19):6300. doi: 10.3390/molecules27196300. PMID: 36234837; PMCID: PMC9571381.

Ardahan Akgül E, Karakul A, Altın A, Doğan P, Hoşgör M, Oral A. Effectiveness of lavender inhalation aromatherapy on pain level and vital signs in children with burns: a randomized controlled trial. *Complement Ther Med*. 2021 Aug;60:102758. doi: 10.1016/j.ctim.2021.102758. Epub 2021 Jul 3. PMID: 34229085.

Oshvandi K, Mirzajani Letomi F, Soltanian AR, Shamsizadeh M. The effects of foot massage on hemodialysis patients' sleep quality and restless leg syndrome: a comparison of lavender and

sweet orange essential oil topical application. *J Complement Integr Med.* 2021 Apr 12;18(4):843-850. doi: 10.1515/jcim-2020-0121. PMID: 33838094.

Ghaderi F, Solhjoui N. The effects of lavender aromatherapy on stress and pain perception in children during dental treatment: A randomized clinical trial. *Complement Ther Clin Pract.* 2020 Aug;40:101182. doi: 10.1016/j.ctcp.2020.101182. Epub 2020 Apr 28. PMID: 32891272.

Ramsey JT, Li Y, Arao Y, Naidu A, Coons LA, Diaz A, Korach KS. Lavender Products Associated With Premature Thelarche and Prepubertal Gynecomastia: Case Reports and Endocrine-Disrupting Chemical Activities. *J Clin Endocrinol Metab.* 2019 Nov 1;104(11):5393-5405. doi: 10.1210/jc.2018-01880. PMID: 31393563; PMCID: PMC6773459.

Woelk H, Schläfke S. A multi-center, double-blind, randomised study of the Lavender oil preparation Silexan in comparison to Lorazepam for generalized anxiety disorder. *Phytomedicine.* 2010 Feb;17(2):94-9. doi: 10.1016/j.phymed.2009.10.006. Epub 2009 Dec 3. PMID: 19962288.

Zhao X, Zhang H, Wu Y, Yu C. The efficacy and safety of St. John's wort extract in depression therapy compared to SSRIs in adults: A meta-analysis of randomized clinical trials. *Adv Clin Exp Med.* 2023 Feb;32(2):151-161. doi: 10.17219/acem/152942. PMID: 36226689.

Canning S, Waterman M, Orsi N, Ayres J, Simpson N, Dye L. The efficacy of *Hypericum perforatum* (St John's wort) for the treatment of premenstrual syndrome: a randomized, double-blind, placebo-controlled trial. *CNS Drugs.* 2010 Mar;24(3):207-25. doi: 10.2165/11530120-000000000-00000. PMID: 20155996.

Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, M Tsatsakis A. The effects of *Crocus sativus* (saffron) and its constituents on nervous system: A review. *Avicenna J Phytomed.* 2015 Sep-Oct;5(5):376-91. PMID: 26468457; PMCID: PMC4599112.

Tabeshpour J, Sobhani F, Sadjadi SA, Hosseinzadeh H, Mohajeri SA, Rajabi O, Taherzadeh Z, Eslami S. A double-blind, randomized, placebo-controlled trial of saffron stigma (*Crocus sativus* L.) in mothers suffering from mild-to-moderate postpartum depression. *Phytomedicine.* 2017 Dec 1;36:145-152. doi: 10.1016/j.phymed.2017.10.005. Epub 2017 Oct 7. PMID: 29157808.

Mazidi M, Shemshian M, Mousavi SH, Norouzy A, Kermani T, Moghiman T, Sadeghi A, Mokhber N, Ghayour-Mobarhan M, Ferns GA. A double-blind, randomized and placebo-controlled trial of Saffron (*Crocus sativus* L.) in the treatment of anxiety and depression. *J Complement Integr Med.* 2016 Jun 1;13(2):195-9. doi: 10.1515/jcim-2015-0043. PMID: 27101556.

Kotanidou EP, Tsinopoulou VR, Giza S, Ntouma S, Angeli C, Chatziandreou M, Tsopeles K, Tseti I, Galli-Tsinopoulou A. The Effect of Saffron Kozanis (*Crocus sativus* L.) Supplementation on Weight Management, Glycemic Markers and Lipid Profile in Adolescents with Obesity: A Double-Blinded Randomized Placebo-Controlled Trial. *Children (Basel).* 2023 Nov 15;10(11):1814. doi: 10.3390/children10111814. PMID: 38002905; PMCID: PMC10670718.